Dante Labs highlights advances in its drug discovery development program, demonstrating the value of genomic data for drug discovery
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — Dante Genomicsa global leader in genomics and precision medicine, highlights significant progress in its drug discovery development program with six drug candidates currently in the company’s pipeline, applying in-house siRNA technology and Dante’s mRNA to rare and common diseases.
Since the company’s inception, Dante has invested in a strong R&D program with the goal of creating end-to-end solutions, from diagnosis to therapy. Dante’s program began with a focus on rare diseases, in response to a patient being diagnosed with a rare disease for which there was no cure. Dante’s pipeline has evolved across multiple therapeutic areas with four drug programs in internal development and two in co-development to achieve validation and external partnership on clinical trials and commercialization.
“Personalized medicine needs personalized data, and our progress over the past 18 months alone demonstrates the value of genomic data for drug development research and discovery,” said Andrea Riposati, CEO of Dante Genomics. “When we founded Dante Genomics, we felt we had a responsibility to provide personalized medicine beyond diagnosis so that no patient faces a diagnosis without effective treatment. It is this holistic approach that puts us challenges and motivates us as a company to accelerate science to save more lives.
Dante has moved its in-house drug programs in rare muscle diseases and rare neurological diseases into the preclinical phase. The newest addition to Dante’s discovery program pipeline is a molecular discovery-stage oncology mRNA therapeutic intended to boost the immune system against certain types of cancer. In co-development with the American biotechnology company Protelica, Dante offers therapies in respiratory diseases and ovarian cancer, both in the non-regulatory preclinical phase.
Development of Dante’s mRNA COVID vaccine program began in early 2021 and recently completed the regulatory preclinical phase and is ready for its first inhuman.
“My academic background has taught me the value of RNA-based therapies, and Dante’s in-house R&D is harnessing mRNA and siRNA technology to accelerate patient throughput from concept to clinic,” said said Mattia Capulli, scientific director of Dante Genomics. “The data and advanced timeline from our mRNA vaccine program demonstrate Dante’s high-quality RNA platform and the reproducibility of this model applied to other clinical therapies.
The company also announced its name change to Dante Genomics to better reflect its global efforts in genomic information and personalized medicine. The name of the company, Dante Genomics, comes from the compound of humanity and science. “Dante” refers to the Italian humanitarian poet and “Genomics” refers to the powerful science that takes place in a genomics lab. Since its inception, Dante Genomics has provided hundreds of thousands of people with affordable, quality genomics solutions to inform their healthcare decisions. The company’s holistic approach to medicine extends from sequencing and variant interpretation to drug discovery.
About Dante Genomics
Dante Genomics is a global genomics information company creating and commercializing a new class of transformative applications for health and longevity based on whole genome sequencing and AI. The company uses its platform to deliver better patient outcomes, from diagnosis to therapy, with assets including one of the largest private genomic databases with research consent, proprietary software designed to unleash the power of large-scale genomic data and proprietary processes that enable an industrial approach to genomics. sequencing.
Vice President of Investor Relations
+39 0862 191 0671
A photo accompanying this ad is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e163117-b6e3-40cc-8ecc-48cd9d72e8ce